The FDA granted Ionis Pharmaceuticals orphan status for ulefnersen, its treatment of amyotrophic lateral sclerosis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis Pharmaceuticals reports Q2 EPS (60c), consensus (90c)
- Ionis reports second quarter 2023 financial results
- IONS Upcoming Earnings Report: What to Expect?
- Ionis Pharmaceuticals, Novartis enter collaboration
- Ionis Pharmacompletes enrollment for Phase 3 CARDIO-TTRansform study
Questions or Comments about the article? Write to editor@tipranks.com